Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group.

J Clin Oncol. 2010 Apr 1;28(10):1772-9. doi: 10.1200/JCO.2009.25.7899. Epub 2010 Mar 1.

2.

Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma.

Baudin E, Droz JP, Paz-Ares L, van Oosterom AT, Cullell-Young M, Schlumberger M.

Am J Clin Oncol. 2010 Feb;33(1):83-8. doi: 10.1097/COC.0b013e31819fdf5e.

PMID:
19704366
3.

A sarcoma at the site of previous extravasation of adriamycin.

Ceulemans J, De Wever I, Sciot R, Debiec-Rychter M, van Oosterom AT.

Sarcoma. 2002;6(4):135-9. doi: 10.1080/1357714021000066386.

4.

Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.

Schöffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, Van Oosterom AT.

Expert Opin Pharmacother. 2008 Jun;9(9):1609-18. doi: 10.1517/14656566.9.9.1609 . Review.

PMID:
18518789
5.

Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer.

Maes T, Wildiers H, Heye S, Demey W, Maleux G, Neven P, Van Oosterom AT, Paridaens R.

Breast Cancer Res Treat. 2008 Jul;110(1):135-42. Epub 2007 Sep 13.

PMID:
17851764
6.

Proteomics in cancer research: methods and application of array-based protein profiling technologies.

Hoeben A, Landuyt B, Botrus G, De Boeck G, Guetens G, Highly M, van Oosterom AT, de Bruijn EA.

Anal Chim Acta. 2006 Mar 30;564(1):19-33. Epub 2005 Aug 30.

PMID:
17723358
7.

A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.

Baur M, van Oosterom AT, Diéras V, Tubiana-Hulin M, Coombes RC, Hatschek T, Murawsky M, Klink-Alakl M, Hudec M, Dittrich C.

J Cancer Res Clin Oncol. 2008 Feb;134(2):125-35. Epub 2007 Jul 17.

PMID:
17636328
8.

Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.

Huygh G, Clement PM, Dumez H, Schöffski P, Wildiers H, Selleslach J, Jimeno JM, Wever ID, Sciot R, Duck L, Van Oosterom AT.

Sarcoma. 2006;2006:56282. Epub 2006 Dec 31.

9.

Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.

Prenen H, Dumez H, Stefan C, Hoeben A, Wouters C, Van Lierde MA, Sciot R, van Oosterom AT, Peeters M, Polus M, Duck L, Gil T, Schöffski P.

Acta Gastroenterol Belg. 2006 Oct-Dec;69(4):367-71.

PMID:
17343077
10.

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.

Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, Issels R, van Oosterom AT, Van Glabbeke M, Blay JY.

Eur J Cancer. 2007 Apr;43(6):974-8. Epub 2007 Mar 2.

PMID:
17336514
11.

A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.

Dumez H, Gall H, Capdeville R, Dutreix C, van Oosterom AT, Giaccone G.

Anticancer Drugs. 2007 Feb;18(2):219-25.

PMID:
17159608
12.

Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.

Dumez H, Martens M, Selleslach J, Guetens G, De Boeck G, Aerts R, De Bruijn EA, Maes RA, van Oosterom AT.

Anticancer Drugs. 2007 Feb;18(2):211-8.

PMID:
17159607
13.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.

Lancet. 2006 Oct 14;368(9544):1329-38.

PMID:
17046465
14.

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.

Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K.

Clin Pharmacol Ther. 2006 Aug;80(2):192-201.

PMID:
16890580
15.
16.

Everolimus alters imatinib blood partition in favour of the erythrocyte.

Prenen H, Guetens G, De Boeck G, Highley M, van Oosterom AT, de Bruijn EA.

J Pharm Pharmacol. 2006 Aug;58(8):1063-6.

PMID:
16872552
17.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group.

Eur J Cancer. 2006 May;42(8):1093-103. Epub 2006 Apr 18.

PMID:
16624552
18.

Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry.

Guetens G, Prenen H, De Boeck G, Highley M, de Wever I, van Oosterom AT, de Bruijn EA.

J Sep Sci. 2006 Feb;29(3):453-9.

PMID:
16544888
19.

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.

Prenen H, Guetens G, de Boeck G, Debiec-Rychter M, Manley P, Schoffski P, van Oosterom AT, de Bruijn E.

Pharmacology. 2006;77(1):11-6. Epub 2006 Mar 8.

PMID:
16534250
20.

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.

J Clin Oncol. 2006 Mar 1;24(7):1195-203.

PMID:
16505440
21.

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Collette L; EORTC Genito-Urinary Cancer Group.

Eur J Cancer. 2006 Jan;42(1):50-4. Epub 2005 Dec 5.

PMID:
16330205
22.

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

Fosså SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, Collette L, de Wit R; EORTC GU Group.

Br J Cancer. 2005 Nov 28;93(11):1209-14.

23.

Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Hoekstra R, Dumez H, Eskens FA, van der Gaast A, Planting AS, de Heus G, Sizer KC, Ravera C, Vaidyanathan S, Bucana C, Fidler IJ, van Oosterom AT, Verweij J.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6908-15.

24.

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR.

J Clin Oncol. 2005 Aug 20;23(24):5795-804.

PMID:
16110036
25.

In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking.

Dumez H, Guetens G, De Boeck G, Highley MS, de Bruijn EA, van Oosterom AT, Maes RA.

Anticancer Drugs. 2005 Sep;16(8):893-5.

PMID:
16096439
26.

In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender.

Dumez H, Guetens G, De Boeck G, Highley MS, de Bruijn EA, van Oosterom AT, Maes RA.

Anticancer Drugs. 2005 Sep;16(8):885-91.

PMID:
16096438
27.

Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometry.

Guetens G, Prenen H, De Boeck G, Van Dongen W, Esmans E, Lemière F, van Oosterom AT, Schöffski P, de Bruijn EA.

J Chromatogr A. 2005 Jul 29;1082(1):2-5.

PMID:
16038188
28.

Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.

Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R.

Histopathology. 2005 Jul;47(1):41-7.

PMID:
15982322
29.
30.

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.

Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT.

Clin Cancer Res. 2005 Feb 15;11(4):1504-11.

31.

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT.

J Clin Oncol. 2005 Feb 1;23(4):889-98.

PMID:
15681535
32.

Vascular endothelial growth factor and angiogenesis.

Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA.

Pharmacol Rev. 2004 Dec;56(4):549-80. Review.

PMID:
15602010
33.

The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.

Dumez H, Guetens G, De Boeck G, Highley MS, Maes RA, van Oosterom AT, de Bruijn EA.

Clin Chem Lab Med. 2004;42(11):1219-27. Review.

PMID:
15576286
34.

Differential protein expression profile in gastrointestinal stromal tumors.

Landuyt B, Prenen H, Debiec-Rychter M, Sciot R, de Bruijn EA, van Oosterom AT.

Amino Acids. 2004 Dec;27(3-4):335-7. Epub 2004 Nov 12.

PMID:
15549490
35.

Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.

Fosså SD, Mickisch GH, De Mulder PH, Horenblas S, van Oosterom AT, van Poppel H, Fey M, Croles JJ, de Prijck L, Van Glabbeke M.

Cancer. 2004 Aug 1;101(3):533-40.

36.

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.

Wachters FM, Groen HJ, Maring JG, Gietema JA, Porro M, Dumez H, de Vries EG, van Oosterom AT.

Br J Cancer. 2004 Jun 14;90(12):2261-7.

37.

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.

de Jonge MJ, Droz JP, Paz-Ares L, van Oosterom AT, de Wit R, Chollet P, Baron B, Lacombe D, Mettinger K, Fumoleau P; EORTC-New Drug Development Group/New Drug Development Program.

Invest New Drugs. 2004 Aug;22(3):329-33.

PMID:
15122081
38.

Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.

Giaccone G, González-Larriba JL, van Oosterom AT, Alfonso R, Smit EF, Martens M, Peters GJ, van der Vijgh WJ, Smith R, Averbuch S, Fandi A.

Ann Oncol. 2004 May;15(5):831-8.

PMID:
15111354
39.

Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study.

D'hondt R, Paridaens R, Wildiers H, Pauwelyn K, Thomas J, Dumez H, Van Oosterom AT.

Anticancer Drugs. 2004 Apr;15(4):341-6.

PMID:
15057137
40.

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.

Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, van Oosterom AT; EORTC Soft Tissue and Bone Sarcoma Group.

Eur J Cancer. 2004 Mar;40(5):689-95.

PMID:
15010069
41.

Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR.

Ismail MS, Wynendaele W, Aerts JL, Paridaens R, Gaafar R, Shakankiry N, Khaled HM, Christiaens MR, Wildiers H, Omar S, Vandekerckhove P, Van Oosterom AT.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):196-201.

42.

Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.

Wildiers H, Ahmed B, Guetens G, De Boeck G, de Bruijn EA, Landuyt W, van Oosterom AT.

Eur J Cancer. 2004 Jan;40(2):284-90.

PMID:
14728944
43.

Unexpected interactions between nicotinamide and CPT-11 in a rhabdomyosarcoma tumor model.

Wildiers H, Ahmed B, Guetens G, De Boeck G, De Bruijn EA, Landuyt W, Van Oosterom AT.

Anticancer Res. 2003 Sep-Oct;23(5A):4055-9.

PMID:
14666718
44.

Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.

Guetens G, De Boeck G, Highley M, Dumez H, Van Oosterom AT, de Bruijn EA.

J Chromatogr A. 2003 Dec 5;1020(1):27-34.

PMID:
14661754
45.

Pharmacology of anticancer drugs in the elderly population.

Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT.

Clin Pharmacokinet. 2003;42(14):1213-42. Review.

PMID:
14606930
46.

Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions.

Ismail MS, Wynendaele W, Aerts JL, Paridaens R, Van Mellaert L, Anné J, Gaafar R, Shakankiry N, Khaled HM, Christiaens MR, Omar S, Vandekerckhove P, Van Oosterom AT.

Ann Oncol. 2003 Aug;14(8):1241-5.

PMID:
12881386
47.

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT.

Br J Cancer. 2003 Jun 16;88(12):1979-86.

48.

Soft tissue sarcomas of adults: state of the translational science.

Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CD, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan MF.

Clin Cancer Res. 2003 Jun;9(6):1941-56. Review.

49.

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.

Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Böttcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT.

Eur J Cancer. 2003 May;39(7):917-26.

PMID:
12706360
50.

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.

van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7.

PMID:
12528778

Supplemental Content

Loading ...
Support Center